Search

Search Results

• 

  25 | A phase II, open-label study to improve compliance and time of treatment after obtaining complete response through a tailored schedule of sonidegib in locally advanced basal cell carcinomas – the SONIBEC trial Monica Variolo^1|2, Carlo Resteghini^1|2, Sara Farinatti^1|2, Andrea Alberti³, Valeria Tovazzi³, Paola Queirolo⁴, Maristella Saponara⁴, Giuseppe Argenziano⁵, Riccardo Marconcini⁶, Ketty Peris⁷, Paola Savoia⁸, Maria Chiara Tronconi¹, Iris Zalaudek⁹, Paolo Ascierto¹⁰, Francesco Spagnolo¹¹, Luigi Lorini¹, Cristina Gurizzan¹, Paolo Bossi^1|2 | ¹Medical Oncology and Haematology Unit, IRCCS Humanitas Research Hospital, Rozzano ^MI; ²Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan; ³Medical Oncology Unit, ASST Spedali Civili, Brescia; ⁴Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan; ⁵Unit of Dermatology, Luigi Vanvitelli University of Campania, Naples; ⁶Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa; ⁷Institute of Dermatology, Catholic University of the Sacred Heart, Rome, Italy; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome; ⁸Department of Health Sciences, University of Eastern Piedmont, Novara; ⁹Department of Dermatology and Venereology, University of Trieste, Ospedale Maggiore, Trieste; ¹⁰Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples; ¹¹Department of Medical Oncology, IRCCS AOU San Martino-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.

  Italian Melanoma Intergroup

  11-12-2025

  https://doi.org/10.4081/dr.2025.10767

  320
• 

  30 | Sonidegib for nevoid basal cell carcinoma (Gorlin) syndrome and EADO stage IIb sporadic basal cell carcinomas: a phase II study (SIBLINGS trial) Sara Farinatti^1|2, Giuseppe Agenziano³, Emi Dika^4|5, Emanuela Passoni⁶, Ketty Peris⁷, Pietro Quaglino⁸, Paola Queirolo⁹, Massimiliano Scalvenzi¹⁰, Iris Zalaudek¹¹, Luigi Lorini¹¹, Cristina Gurizzan¹, Monica Variolo^1|2, Paolo Bossi*^1|2, Carlo Resteghini*^1|2 | ¹Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milano; ²Department of Biomedical Sciences, Humanitas University, Rozzano ^MI; ³Unit of Dermatology, Luigi Vanvitelli University of Campania, Naples; ⁴Oncologic Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna; ⁵Department of Medical and Surgical Sciences, DIMEC, University of Bologna, Bologna; ⁶Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan; ⁷Institute of Dermatology, Catholic University of the Sacred Heart, Rome; Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome; ⁸Dermatologic Clinic, University of Turin Medical School, Turin; ⁹Medical Oncology Unit; ¹⁰Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples; ¹¹Department of Dermatology and Venereology, University of Trieste, Ospedale Maggiore, Trieste, Italy. *Contributed equally.

  Italian Melanoma Intergroup

  11-12-2025

  https://doi.org/10.4081/dr.2025.10772

  336